Grifols S.A. (GRFS)
undefined
undefined%
At close: undefined
7.33
-0.48%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives.

The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions.

The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.

It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.

The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices.

The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals.

The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products.

Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions.

The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems.

Grifols, S.A. has a technology collaboration agreement with Mondragon.

The company was founded in 1940 and is headquartered in Barcelona, Spain.

Grifols S.A.
Grifols S.A. logo
Country ES
IPO Date Jun 2, 2011
Industry Drug Manufacturers - General
Sector Healthcare
Employees 23,000
CEO Jose Ignacio Abia Buenache

Contact Details

Address:
Avinguda de la Generalitat, 152
Barcelona,
ES
Website https://www.grifols.com

Stock Details

Ticker Symbol GRFS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001438569
CUSIP Number 398438408
ISIN Number US3984384087
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Jose Ignacio Abia Buenache Chief Executive Officer & Director
Alfredo Arroyo Guerra CPA Chief Financial Officer & Vice President
Lluis Pons Gomez Senior Vice President of Strategy & Chief Operating Officer Office
Camille Alpi Chief Human Resources & Talent Officer
David Ian Bell Chief Corporate Development, Legal & Data Protection Officer
Maria Teresa-Rioné Llano Chief Communications Officer
Nuria Pascual Lapeña Vice President of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
Sergio Roura Adell President of Commercial Tech Support
Vicente Blanquer Torre Chief Quality Officer
Víctor Grifols Deu Executive Director

Latest SEC Filings

Date Type Title
Dec 11, 2024 6-K Filing
Dec 09, 2024 6-K Filing
Nov 27, 2024 6-K Filing
Nov 19, 2024 6-K Filing
Nov 19, 2024 6-K Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 6-K Filing
Sep 25, 2024 6-K Filing
Sep 23, 2024 6-K Filing
Jul 30, 2024 6-K Filing